Drugs / Cytokine Induced Memory-like Natural Killer (CIML NK) Cells
Cytokine Induced Memory-like Natural Killer (CIML NK) Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06318871 | Aug 2024 → Feb 2027 expected | MIT family translocation renal cell carcinoma, chromophobe renal cell carcinoma, urothelial carcinoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cytokine Induced Memory-like Natural Killer (CIML NK) Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06318871 ↗ |
| Modality | Cell therapy | “a NK cell therapy” NCT06318871 ↗ |
| Route | Intravenous | “via intravenous (into the vein) infusion per protocol” NCT06318871 ↗ |